FYERS
Home
/
Stocks
/
Profit Loss
/
Anthem Biosciences Profit & Loss

Anthem Biosciences Profit & Loss

Consolidated
Standalone
Quarterly
Yearly
₹
%
Name
Net Revenue
Other Income
Total Revenue
Total Expenditure
Operating Profit
Interest Expense
PBT
Net Profit
Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024
₹418 Cr₹611 Cr₹423 Cr₹550 Cr₹540 Cr₹483 Cr₹498 Cr₹525 Cr₹339 Cr
₹25 Cr₹51 Cr₹34 Cr₹48 Cr₹23 Cr₹14 Cr₹24 Cr₹28 Cr₹19 Cr
₹443 Cr₹662 Cr₹457 Cr₹598 Cr₹563 Cr₹497 Cr₹522 Cr₹553 Cr₹358 Cr
₹298 Cr₹383 Cr₹300 Cr₹366 Cr₹375 Cr₹318 Cr₹359 Cr₹350 Cr₹236 Cr
₹175 Cr₹318 Cr₹191 Cr₹266 Cr₹214 Cr₹209 Cr₹184 Cr₹223 Cr₹140 Cr
₹89 L₹2 Cr₹35 L₹3 Cr₹2 Cr₹52 L₹3 Cr₹4 Cr₹4 Cr
₹145 Cr₹278 Cr₹130 Cr₹230 Cr₹186 Cr₹178 Cr₹161 Cr₹200 Cr₹118 Cr
₹120 Cr₹190 Cr₹93 Cr₹173 Cr₹136 Cr₹83 Cr₹124 Cr₹162 Cr₹82 Cr

Share Price Live Stats

Open (₹)938.10
Volume (₹)7.04 L
High (₹)952.00
Upper Circuit1,130.75
Low (₹)932.70
Lower Circuit753.85
Prev Close942.30
52W High (₹)977.55
Price940.25
52W Low (₹)579.15

Share Market Cap & Key Ratios Overview

M.Cap (₹)53067.40 Cr
Div. Yield (%)0.21
PE Ratio92.14
Debt to Equity0.02
Price to Book12.25
Book Value53.57
EPS (TTM)10.22
Face Value2.00
ROE (%)21.98

Stock Analysis (SWOT)

StrengthsWeaknessesOpportunitiesThreats
1. Premium insight available after login
2. Sign in to view full SWOT analysis
3. Unlock strengths, weaknesses, opportunities & threats
Sign in to view
Open a free Demat account in minutes to start investing and screening .
LoginSign Up

QVT

Quality
0/100-
Valuation
0/100-
Technical
0/100-
Sign in to view
Open a free Demat account in minutes to start investing and screening .
LoginSign Up

Peer Stocks

1 week
1 month
1 year
Name
SUNPHARMANSE
DIVISLABNSE
TORNTPHARMNSE
ZYDUSLIFENSE
CIPLANSE
LAURUSLABSNSE
AUROPHARMANSE
DRREDDYNSE
LUPINNSE
MANKINDNSE
ANTHEMNSE
LTP
1W Low
1W High
Market cap (₹)
1839.6-59.4 (-3.13%)
1839
1907.80
4,47,236Cr
9321.5+221.5 (2.43%)
9119.50
9615
2,49,673Cr
4961+104 (2.14%)
4823
5000
1,87,460Cr
1121.7+1.7 (0.15%)
1104.60
1167.70
1,11,521Cr
1359.5-25.5 (-1.84%)
1347.70
1398.40
1,11,484Cr
1978+138 (7.50%)
1832.70
1978
1,04,604Cr
1670+16.9 (1.02%)
1646
1704
96,031Cr
1170.8+19.8 (1.72%)
1130
1182
95,220Cr
2098.4-11.6 (-0.55%)
2058
2135.50
94,883Cr
2273.5-54.4 (-2.34%)
2222
2331.60
92,770Cr
940.25+6.2 (0.66%)
920
977.55
53,067Cr

Key Highlights of Anthem Biosciences Ltd’s P&L

In 2026-03-31, Anthem Biosciences Ltd reported total revenue of ₹2280.11Cr, compared with ₹1930.28Cr in 2025-03-31, reflecting Anthem Biosciences Ltd turnover.

Depreciation was ₹134.07Cr and finance costs were ₹7.05Cr in 2026-03-31

Profit Before Tax (PBT) has been ₹824.24Cr in 2026-03-31 as compared to ₹656.87Cr in 2025-03-31.

Net Profit (PAT) was ₹591.79Cr in 2026-03-31 compared with ₹451.26Cr in 2025-03-31.

Earnings per share (EPS) were ₹10.54 in 2026-03-31, compared with ₹8.07 in 2025-03-31.